Advertisement

Reactions Weekly

, Volume 1765, Issue 1, pp 129–129 | Cite as

Crizotinib

Acquired F1174L mutation after resistance in large-cell neuroendocrine carcinoma: case report
Case report
  • 13 Downloads

Reference

  1. Tian P, et al. A case of large-cell neuroendocrine carcinoma harboring rare ALK fusion with initial response to the ALK inhibitor crizotinib and acquired F1174L mutation after resistance. Precision Clinical Medicine 2: No. 1, Mar 2019. Available from: URL: http://doi.org/10.1093/pcmedi/pbz005 - China

Copyright information

© Springer International Publishing AG 2019

Personalised recommendations